Breast cancer, version 4.2021 featured updates to the NCCN guidelines

William J. Gradishar; Meena S. Moran; Jame Abraham; Rebecca Aft; Doreen Agnese; Kimberly H. Allison; Sarah L. Blair; Harold J. Burstein; Chau Dang; Anthony D. Elias; Sharon H. Giordano; Matthew P. Goetz; Lori J. Goldstein; Sara A. Hurvitz; Steven J. Isakoff; Rachel C. Jankowitz; Sara H. Javid; Jairam Krishnamurthy; Marilyn Leitch; Janice Lyons; Jennifer Matro; Ingrid A. Mayer; Joanne Mortimer; Ruth M. O'Regan; Sameer A. Patel; Lori J. Pierce; Hope S. Rugo; Amy Sitapati; Karen Lisa Smith; Mary Lou Smith; Hatem Soliman; Erica M. Stringer-Reasor; Melinda L. Telli; John H. Ward; Kari B. Wisinski; Jessica S. Young; Jennifer L. Burns; Rashmi Kumar

doi:10.6004/jnccn.2021.0023

Breast cancer, version 4.2021 featured updates to the NCCN guidelines

William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice LyonsJennifer Matro, Ingrid A. Mayer, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica S. Young, Jennifer L. Burns, Rashmi Kumar

Medical Oncology

Research output: Contribution to journal › Article › peer-review

Abstract

The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer-focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor-positive, HER2-negative breast cancer.

Original language	English (US)
Pages (from-to)	484-494
Number of pages	11
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	19
Issue number	5
DOIs	https://doi.org/10.6004/jnccn.2021.0023
State	Published - May 2021

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2021.0023

Cite this

Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P., Goldstein, L. J., Hurvitz, S. A., Isakoff, S. J., Jankowitz, R. C., Javid, S. H., Krishnamurthy, J., Leitch, M., ... Kumar, R. (2021). Breast cancer, version 4.2021 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 19(5), 484-494. https://doi.org/10.6004/jnccn.2021.0023

Gradishar, WJ, Moran, MS, Abraham, J, Aft, R, Agnese, D, Allison, KH, Blair, SL, Burstein, HJ, Dang, C, Elias, AD, Giordano, SH, Goetz, MP, Goldstein, LJ, Hurvitz, SA, Isakoff, SJ, Jankowitz, RC, Javid, SH, Krishnamurthy, J, Leitch, M, Lyons, J, Matro, J, Mayer, IA, Mortimer, J, O'Regan, RM, Patel, SA, Pierce, LJ, Rugo, HS, Sitapati, A, Smith, KL, Smith, ML, Soliman, H, Stringer-Reasor, EM, Telli, ML, Ward, JH, Wisinski, KB, Young, JS, Burns, JL & Kumar, R 2021, 'Breast cancer, version 4.2021 featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 19, no. 5, pp. 484-494. https://doi.org/10.6004/jnccn.2021.0023

@article{c2ff609208e74a2bb52c5efb8a395648,

title = "Breast cancer, version 4.2021 featured updates to the NCCN guidelines",

abstract = "The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer-focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor-positive, HER2-negative breast cancer.",

author = "Gradishar, {William J.} and Moran, {Meena S.} and Jame Abraham and Rebecca Aft and Doreen Agnese and Allison, {Kimberly H.} and Blair, {Sarah L.} and Burstein, {Harold J.} and Chau Dang and Elias, {Anthony D.} and Giordano, {Sharon H.} and Goetz, {Matthew P.} and Goldstein, {Lori J.} and Hurvitz, {Sara A.} and Isakoff, {Steven J.} and Jankowitz, {Rachel C.} and Javid, {Sara H.} and Jairam Krishnamurthy and Marilyn Leitch and Janice Lyons and Jennifer Matro and Mayer, {Ingrid A.} and Joanne Mortimer and O'Regan, {Ruth M.} and Patel, {Sameer A.} and Pierce, {Lori J.} and Rugo, {Hope S.} and Amy Sitapati and Smith, {Karen Lisa} and Smith, {Mary Lou} and Hatem Soliman and Stringer-Reasor, {Erica M.} and Telli, {Melinda L.} and Ward, {John H.} and Wisinski, {Kari B.} and Young, {Jessica S.} and Burns, {Jennifer L.} and Rashmi Kumar",

year = "2021",

month = may,

doi = "10.6004/jnccn.2021.0023",

language = "English (US)",

volume = "19",

pages = "484--494",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "5",

}

TY - JOUR

T1 - Breast cancer, version 4.2021 featured updates to the NCCN guidelines

AU - Gradishar, William J.

AU - Moran, Meena S.

AU - Abraham, Jame

AU - Aft, Rebecca

AU - Agnese, Doreen

AU - Allison, Kimberly H.

AU - Blair, Sarah L.

AU - Burstein, Harold J.

AU - Dang, Chau

AU - Elias, Anthony D.

AU - Giordano, Sharon H.

AU - Goetz, Matthew P.

AU - Goldstein, Lori J.

AU - Hurvitz, Sara A.

AU - Isakoff, Steven J.

AU - Jankowitz, Rachel C.

AU - Javid, Sara H.

AU - Krishnamurthy, Jairam

AU - Leitch, Marilyn

AU - Lyons, Janice

AU - Matro, Jennifer

AU - Mayer, Ingrid A.

AU - Mortimer, Joanne

AU - O'Regan, Ruth M.

AU - Patel, Sameer A.

AU - Pierce, Lori J.

AU - Rugo, Hope S.

AU - Sitapati, Amy

AU - Smith, Karen Lisa

AU - Smith, Mary Lou

AU - Soliman, Hatem

AU - Stringer-Reasor, Erica M.

AU - Telli, Melinda L.

AU - Ward, John H.

AU - Wisinski, Kari B.

AU - Young, Jessica S.

AU - Burns, Jennifer L.

AU - Kumar, Rashmi

PY - 2021/5

Y1 - 2021/5

N2 - The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer-focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor-positive, HER2-negative breast cancer.

AB - The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer-focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor-positive, HER2-negative breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85106923703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106923703&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2021.0023

DO - 10.6004/jnccn.2021.0023

M3 - Article

C2 - 34030128

AN - SCOPUS:85106923703

SN - 1540-1405

VL - 19

SP - 484

EP - 494

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 5

ER -

Breast cancer, version 4.2021 featured updates to the NCCN guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this